^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:tanespimycin (BMS-722782) (HSP90 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    ...we tested a panel of HPV-negative HNSCC cell lines with 17-AAG...In these cell lines, there was no clear difference to treatment with 17-AAG although there appeared to be a trend towards increased resistance of those cells with PI3K mutations compared to those cells that did not contain a PI3K mutation....the hotspot E545K and H1047R mutations conferred decreased, rather than increased, sensitivity...
    DOI:
    10.1001/jamaoto.2015.0471